Charts

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Kensho New Economies Composite ETF (KOMP), we found that the implied analyst target price for the ETF based upon its underlying holdings is $54.82 per unit.

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and MTD, and their areas of focus.

The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discover seven penny stocks to buy primed for significant gains in Q2 2024. Don't miss out on these picks or your portfolio could suffer. The post The 7 Best Penny Stocks to Buy in Q2 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

In this article, we will take a detailed look at Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks. For a quick overview of such stocks, read our article Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 5 Stocks. Billionaire Stanley Druckenmiller is one of the most revered investors in the Wall Street. […]

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time).

AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.

This article is a recap of how 7 artificial intelligence stock categories did in February, and YTD, compared to each other to help you  make prudent investment decisions accordingly. 

AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center.

Grand View Research says the global "AI in drug discovery" market should expand at a CAGR of 30% between now, and 2030 which Morgan Stanley believes will lead to 50 novel therapies over the next decade, with annual sales in excess of $50 billion.

Key Insights Institutions' substantial holdings in AbCellera Biologics implies that they have significant influence...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. The post 3 Highly Rated Biotech Stocks to Buy for 300% Gains appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:

Investors in AbCellera Biologics Inc (ABCL) saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABCL options chain for the new March 15th contracts and identified one put and one call contract of particular interest.

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript February 20, 2024 AbCellera Biologics Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.14. AbCellera Biologics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. […]

Q4 2023 Abcellera Biologics Inc Earnings Call

ABCL earnings call for the period ending December 31, 2023.

Although the revenue and EPS for AbCellera Biologics Inc. (ABCL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Revenue Declines as Company Focuses on Internal Programs and Strategic Partnerships

AbCellera Biologics (NASDAQ:ABCL) reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:05 PM. Here's what investors need ...

AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue ...

A synopsis of the performances of each of the 9 different artificial intelligence stock categories last week, and YTD, along with a description of what makes up each category and the stocks included in each.

The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 

Techne (TECH) delivered earnings and revenue surprises of -4.76% and 1.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Baillie Gifford (Trades, Portfolio), a renowned investment management firm, has recently altered its investment in AbCellera Biologics Inc (NASDAQ:ABCL), a Canadian biotechnology company. This transaction involved the sale of 2,159,853 shares at a price of $4.83 per share, which has impacted Baillie Gifford (Trades, Portfolio)'s stake in the company and its overall investment strategy.

AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

These innovation-oriented companies could take flight this year.

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Kensho New Economies Composite ETF (KOMP), we found that the implied analyst target price for the ETF based upon its underlying holdings is $52.09 per unit.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. The post AI Meets Biotech: 3 Top Stocks Transforming Medical Science appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to streamline drug discovery and development.

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 8, AbCellera Biologics Inc's Director, John S..

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 25.6% to $0.32 during Friday's pre-market session. The company's ...

ABCL earnings call for the period ending September 30, 2023.

Gainers DermTech (NASDAQ:DMTK) shares rose 23.6% to $1.73 during Thursday's after-market session. The company's market cap stands at ...

AbCellera Reports Q3 2023 Business Results

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

AbCellera Announces Two T-Cell Engager Presentations at SITC 2023

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

Benchmarkanalyst Robert Wasserman reiterated a Buy rating onAbCellera Biologics Inc.(NASDAQ: ABCL),lowering the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. The post 3 AI Stocks You’ll Regret Not Buying Soon appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The $1 Investment You MUST Take Advantage of Right Now The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors